

What science can do

AstraZeneca Development Pipeline as at 9 February 2023



References to Notes and page numbers, and capitalised terms not defined in this supplement, can be found in AstraZeneca's Annual Report and Form 20-F Information 2022 at www.astrazeneca.com/annualreport2022.

AstraZeneca-sponsored or -directed trial

New Molecular Entities (NMEs) and significant indications

First major market regulatory submission date and submission status is provided for assets in Phase III or beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Phase I

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0466	BCL2/xL	PP	haematological malignancies
AZD1390	ATM inhibitor		glioblastoma
AZD7789	PD1/TIM3 bispecific mAb		solid tumours, haematological malignancies
AZD8853	GDF-15		solid tumours
AZD9574	PARP inhibitor		advanced solid malignancies
AZD9592	EGFR/cMET		solid tumours
IPH5201	CD39	PP	solid tumours
volrustomig + lenvatinib	PD-1/CTLA-4 bispecific mAb + VEGF		advanced renal cell carcinoma
CVRM			
AZD0186	GLP1R agonism		type-2 diabetes
AZD0780	PCSK9		dyslipidaemia
AZD2373	podocyte health		nephropathy
AZD2693	NASH resolution		non-alcoholic steatohepatitis
AZD3366	CD39L3		cardiovascular disease
AZD3427	relaxin mimetic		cardiovascular disease
AZD5462	RXFP1 agonist		cardiovascular disease
AZD6234	peptide		obesity with related comorbidities
AZD7503	ASO		non-alcoholic steatohepatitis
Respiratory & Immunology			
AZD4604	inhaled JAK1 inhibitor		asthma
AZD5055	porcupine inhibitor		idiopathic pulmonary fibrosis
AZD6793	IRAK4 inhibitor		inflammatory diseases
AZD7798	humanised mAb targets T cells subset		Crohn's disease
AZD8630	inhaled TSLP FAb	PP	asthma
Rare Disease			
ALXN1820	anti-properdin bispecific		haematology
ALXN1850	next gen TNSALP ERT		hypophosphatasia
ALXN1910	next gen TNSALP ERT		bone metabolism
ALXN2030	siRNA targeting complement C3		nephrology
ALXN2080	oral factor D inhibitor		healthy volunteers
NI006	TTR depleter	PP	transthyretin amyloid cardiomyopathy
Other Medicines			
AZD4041	orexin 1 receptor antagonist	PP	opioid use disorder
MEDI0618	PAR2 antagonist mAb	Phase I/IIa	osteoarthritis pain
MEDI1814	amyloid beta mAb	PP	Alzheimer's disease

Phase II

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0171 + <i>Imfinzi</i> + CTx	anti-LIF mAb + PD-L1 mAb + CTx		1st-line metastatic pancreatic ductal adenocarcinoma
AZD4573	CDK9 inhibitor		haematological malignancies
AZD4573 + <i>Calquence</i>	CDK9 inhibitor + BTK inhibitor		haematological malignancies
AZD5305	PARP1Sel		solid tumours
AZD8205	B7-H4 targeting ADC		solid tumours
camizestrant	selective oestrogen receptor degrader		oestrogen receptor +ve breast cancer
capiasertib	AKT inhibitor		prostate cancer
cerlasertib	ATR inhibitor		solid tumours
<i>Imfinzi</i> + monalizumab	PD-L1 mAb + NKG2A mAb	PP	solid tumours
oleclumab + CTx or <i>Imfinzi</i> + oleclumab + CTx	CD73 mAb + CTx or PD-L1 mAb + CD73 mAb + CTx		metastatic pancreatic cancer
rilvegostomig (AZD2936) ARTEMIDE-1	PD1/TIGIT bispecific mAb	PP	solid tumours
volrustomig	PD-1/CTLA-4 bispecific mAb		solid tumours

Development Pipeline

continued

Phase II continued

Compound	Mechanism	Additional Information	Area Under Investigation
CVRM			
balcinrenone/dapagliflozin	MR modulator + SGLT2 inhibitor		heart failure with CKD
cotadutide	GLP-1/glucagon dual agonist	Phase IIb/III	non-alcoholic steatohepatitis (NASH)
MEDI6570	LOX-1 mAb		cardiovascular disease
mitiperstat	myeloperoxidase		heart failure with preserved ejection fraction/NASH
tozorakimab	IL-33 mAb		diabetic kidney disease
zibotentan/dapagliflozin	endothelin A receptor antagonist + SGLT2 inhibitor		chronic kidney disease
Respiratory & Immunology			
atuliflapon	FLAP inhibitor		asthma
brazikumab EXPEDITION	IL-23 mAb		ulcerative colitis
elarekibep (AZD1402)	inhaled IL-4Ra	PP	asthma
mitiperstat	myeloperoxidase		COPD
tozorakimab FRONTIER 3	IL-33 mAb		asthma
Rare Disease			
danicopan	oral factor D inhibitor		geographic atrophy
vemircopan	oral factor D inhibitor		paroxysmal nocturnal haemoglobinuria
vemircopan	oral factor D inhibitor		generalised myasthenia gravis
vemircopan	oral factor D inhibitor		proliferative lupus nephritis or immunoglobulin A nephropathy
Other Medicines			
MEDI1341	alpha synuclein mAb	PP	multiple system atrophy/Parkinson's disease
MEDI7352	NGF/TNF bispecific mAb		osteoarthritis pain and painful diabetic neuropathy

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets)

Compound	Mechanism	Area Under Investigation	Additional Information	Estimated submission/ submission status
Oncology				
camizestrant + CDK4/6i SERENA-6	selective oestrogen receptor degrader + CDK4/6 inhibitors	1st-line HR+ HER2- ESR1m breast cancer		2024
camizestrant + palbociclib SERENA-4	selective oestrogen receptor degrader + CDK4/6 inhibitor	1st-line HR+ HER2- breast cancer		>2024
capivasertib + abiraterone CAPItello-281	AKT inhibitor + abiraterone	PTEN deficient metastatic hormone sensitive prostate cancer		>2024
capivasertib + CTx CAPItello-290	AKT inhibitor + CTx	1st-line metastatic triple negative breast cancer		H2 2023
capivasertib + docetaxel CAPItello-280	AKT inhibitor + docetaxel	mCRPC prostate cancer		>2024
capivasertib + fulvestrant + palbociclib CAPItello-292	AKT inhibitor + fulvestrant + CDK4/6 inhibitor	1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer		>2024
capivasertib + fulvestrant CAPItello-291	AKT inhibitor + fulvestrant	2nd-line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer		H1 2023
ceralasertib + Imfinzi LATIFY	ATR inhibitor + PDL-1 mAb	non-small cell lung cancer (NSCLC)		>2024
ceralasertib + Imfinzi MONETTE	ATR inhibitor + PDL-1 mAb	melanoma	Phase II	>2024
datopotamab deruxtecan AVANZAR	TROP2 ADC	1st-line NSCLC, squamous and non-squamous 1L NSCLC, TROP2 BM+	PP	>2024
datopotamab deruxtecan TROPION-Lung07	TROP2 ADC	1st-line NSCLC PD-L1 <50% non-squamous	PP	>2024
datopotamab deruxtecan TROPION-Lung08	TROP2 ADC	1st-line metastatic NSCLC without actionable genomic alterations and PD-L1 TPS ≥50%	PP	>2024
datopotamab deruxtecan TROPION-Breast01	TROP2 ADC	2nd-3rd-line HR+ HER2- breast cancer	PP	>2024
datopotamab deruxtecan TROPION-Breast02	TROP2 ADC	1st-line triple negative breast cancer	PP	>2024
datopotamab deruxtecan TROPION-Breast03	TROP2 ADC	adjuvant residual disease triple negative breast cancer	PP	>2024
datopotamab deruxtecan TROPION-Lung01	TROP2 ADC	2nd-line+ NSCLC with or without actionable genomic alterations	PP	H1 2023
Imfinzi + Imjudo HIMALAYA	PD-L1 mAb + CTLA-4 mAb	1st-line hepatocellular carcinoma	PP	Launched

Development Pipeline

continued

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets) continued

Compound	Mechanism	Area Under Investigation	Additional Information	Estimated submission/ submission status
Oncology				
<i>Imfinzi</i> +/- oleclumab +/- monalizumab PACIFIC-9	PD-L1 + NKG2A or PD-L1 + CD73	unresectable stage III NSCLC	PP	>2024
CVRM				
<i>Andexxa</i>	anti-factor Xa reversal	acute major bleed		Launched
eplontersen	ligand-conjugated antisense	patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM)	PP	>2024
eplontersen	ligand-conjugated antisense	patients with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN)	PP	H1 2023
roxadustat OLYMPUS ROCKIES	hypoxia-inducible factor prolyl hydroxylase inhibitor	anaemia in chronic kidney disease/ end-stage renal disease	PP	Launched
Respiratory & Immunology				
<i>Airsupra</i> (PT010)	ICS/SABA	asthma	PP	Approved
brazikumab INTREPID	IL-23 mAb	Crohn's disease	Phase II/III	>2024
<i>Fasenra</i> CALIMA SIROCCO ZONDA BISE BORA GREGALE MIRACLE	IL-5R mAb	severe uncontrolled asthma	PP	Launched
<i>Saphnelo</i> TULIP 1 & TULIP 2 AZALEA (China)	Type I IFN receptor mAb	systemic lupus erythematosus	PP	Launched
<i>Tezspire</i> NAVIGATOR DIRECTION	TSLP mAb	severe uncontrolled asthma	PP	Launched
tozorakimab OBERON TITANIA	IL-33 mAb	chronic obstructive pulmonary disease		>2024
tozorakimab TILIA	IL-33 mAb	acute respiratory failure		2024
Vaccine & Immune Therapies				
AZD3152 SUPERNOVA	SARS-CoV-2 LAAB	prevention of COVID-19	Phase I/III	H2 2023
<i>Beyfortus</i>	RSV mAb-YTE	passive RSV immunisation	PP	Approved
<i>Evusheld</i>	COVID-19 LAAB combination	prevention and treatment of COVID-19		Launched
Rare Disease				
acoramidis	oral TTR stabiliser	transthyretin amyloid cardiomyopathy	PP	2024
ALXN1840	bis-choline tetrathiomolybdate	Wilson's disease		H2 2023
anselamimab (CAEL-101)	fibril-reactive mAb	AL amyloidosis		2024
danicopan	oral factor D inhibitor	paroxysmal nocturnal haemoglobinuria with extravascular haemolysis		H1 2023
gefurulimab	humanised bispecific VHH antibody	generalised myasthenia gravis		>2024
<i>Koselugo</i> / selumetinib SPRINT	MEK inhibitor	paediatric neurofibromatosis type-1	PP	Launched

Development Pipeline

continued

Significant Life-cycle Management

First major market regulatory submission date and submission status is provided for assets in Phase III or beyond. Projects in Phase III unless otherwise noted.

Compound	Mechanism	Area Under Investigation	Additional Information	Estimated submission/ submission status
Oncology				
Calquence + R-CHOP ESCALADE	BTK inhibitor + R-CHOP	1st-line diffuse large B cell lymphoma		>2024
Calquence + venetoclax + obinutuzumab AMPLIFY	BTK inhibitor + BCL-2 inhibitor + anti-CD20 mAb	1st-line chronic lymphocytic leukaemia	PP	>2024
Calquence ASCEND	BTK inhibitor	relapsed/refractory chronic lymphocytic leukaemia	PP	Launched
Calquence ECHO	BTK inhibitor	1st-line mantle cell lymphoma	PP	2024
Calquence ELEVATE-TN	BTK inhibitor	1st-line chronic lymphocytic leukaemia	PP	Launched
Enhertu (platform) DESTINY-Breast07	HER2 targeting ADC	HER2+ breast cancer	PP Phase II	
Enhertu (platform) DESTINY-Breast08	HER2 targeting ADC	HER2-low breast cancer	PP Phase I	
Enhertu DESTINY-Breast02	HER2 targeting ADC	HER2+, unresectable and/or metastatic breast cancer pretreated with prior standard of care HER2 therapies, including T-DM1	PP	H1 2023
Enhertu DESTINY-Breast03	HER2 targeting ADC	HER2+, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane	PP	Launched
Enhertu DESTINY-Breast04	HER2 targeting ADC	HER2-low, unresectable and/or metastatic breast cancer subjects	PP	Launched
Enhertu DESTINY-Breast05	HER2 targeting ADC	HER2+ post-neoadjuvant high-risk breast cancer	PP	>2024
Enhertu DESTINY-Breast06	HER2 targeting ADC	post-ET HER2-low/HR+ breast cancer 2L	PP	2024
Enhertu DESTINY-Breast09	HER2 targeting ADC	1st-line HER2+ breast cancer	PP	>2024
Enhertu DESTINY-Breast11	HER2 targeting ADC	neoadjuvant HER2+ breast cancer	PP	2024
Enhertu DESTINY-Gastric01	HER2 targeting ADC	HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens	PP Phase II	Launched
Enhertu DESTINY-Gastric04	HER2 targeting ADC	2nd-line HER2+ gastric cancer	PP	2024
Enhertu DESTINY-Lung01	HER2 targeting ADC	HER2-over-expressing or -mutated, unresectable and/or metastatic NSCLC	PP Phase II	Launched
Enhertu DESTINY-Lung04	HER2 targeting ADC	1st-line HER2 mutated NSCLC	PP	>2024
Enhertu DESTINY-PanTumour01	HER2 targeting ADC	HER2 mutant tumours	PP Phase II	
Enhertu DESTINY-PanTumour02	HER2 targeting ADC	HER2 expressing solid tumours	PP Phase II	
Imfinzi (platform) BEGONIA	PD-L1 mAb with paclitaxel and multiple novel oncology therapies	1st-line metastatic triple negative breast cancer	Phase II	
Imfinzi (platform) COAST	PD-L1 mAb + multiple novel oncology therapies	NSCLC	PP Phase II	
Imfinzi (platform) HUDSON	PD-L1 mAb + multiple novel oncology therapies	post-IO NSCLC	Phase II	
Imfinzi (platform) MAGELLAN	D-L1 mAb + multiple novel oncology therapies +/- CTx	1st-line metastatic NSCLC	PP Phase II	
Imfinzi (platform) NeoCOAST	PD-L1 mAb + multiple novel oncology therapies	NSCLC	PP Phase II	
Imfinzi + CRT KUNLUN	PD-L1 mAb + CRT	locally advanced oesophageal squamous cell carcinoma	PP	>2024
Imfinzi + CRT PACIFIC-2	PD-L1 mAb + CRT	locally-advanced (stage III) NSCLC	PP	2024
Imfinzi + CRT PACIFIC-5 (China)	PD-L1 mAb + CRT	locally-advanced (stage III) NSCLC	PP	H1 2023
Imfinzi + CTx neoadjuvant AEGEAN	PD-L1 mAb + CTx	locally-advanced (stage II-III) NSCLC		H2 2023
Imfinzi + CTx NIAGARA	PD-L1 mAb + CTx	muscle invasive bladder cancer		H2 2023
Imfinzi + CTx TOPAZ-1	PD-L1 mAb + CTx	1st-line biliary tract cancer	PP	Launched
Imfinzi + domvanalimab (AB154) + CTx PACIFIC-8	PD-L1 mAb + TIGIT	unresectable stage III NSCLC	PP	>2024
Imfinzi + EV +/- Imjudo VOLGA	PD-L1 + nectin-4 targeting ADC +/- CTLA4	muscle invasive bladder cancer		>2024

Development Pipeline

continued

Significant Life-cycle Management continued

Compound	Mechanism	Area Under Investigation	Additional Information	Estimated submission/ submission status
<i>Imfinzi</i> + FLOT MATTERHORN	PD-L1 mAb + CTx	neoadjuvant/adjuvant gastric cancer	PP	>2024
<i>Imfinzi</i> + <i>Imjudo</i> + SoC NILE	PL-L1 mAb + CTLA-4 mAb + SoC	1st-line urothelial cancer		H2 2023
<i>Imfinzi</i> + <i>Imjudo</i> + TACE +/- lenvatinib EMERALD-3	PD-L1 + CTLA4 + VEGF +/- chemo-embolisation	locoregional hepatocellular carcinoma		>2024
<i>Imfinzi</i> + <i>Lynparza</i> ORION	PD-L1 mAb + PARP inhibitor	1st-line metastatic NSCLC	PP Phase II	
<i>Imfinzi</i> + VEGF + TACE EMERALD-1	PD-L1 mAb + VEGF + TACE	locoregional hepatocellular carcinoma	PP	2024
<i>Imfinzi</i> + VEGF EMERALD-2	PD-L1 mAb + VEGF	adjuvant hepatocellular carcinoma	PP	H2 2023
<i>Imfinzi</i> +/- <i>Imjudo</i> + CRT ADRIATIC	PD-L1 mAb +/- CTLA-4 mAb + CRT	1st-line limited-stage small-cell lung cancer	PP	2024
<i>Imfinzi</i> +/- <i>Imjudo</i> + CTx POSEIDON	PD-L1 mAb +/- CTLA-4 mAb + CTx	1st-line NSCLC		Launched
<i>Imfinzi</i> post-SBRT PACIFIC-4	PD-L1 mAb post-SBRT	stage I/II NSCLC	PP	>2024
<i>Imfinzi</i> POTOMAC	PD-L1 mAb	non-muscle invasive bladder cancer		>2024
<i>Lynparza</i> (basket) LYNK002	PARP inhibitor	HRRm cancer	PP Phase II	
<i>Lynparza</i> + abiraterone PROpel	PARP inhibitor + NHA	prostate cancer	PP	Launched
<i>Lynparza</i> + <i>Imfinzi</i> + bevacizumab DUO-O	PARP inhibitor + PD-L1 mAb + VEGF inhibitor	1st-line ovarian cancer	PP	2024
<i>Lynparza</i> + <i>Imfinzi</i> DUO-E	PARP inhibitor + PD-L1 mAb	1st-line endometrial cancer	PP	2024
<i>Lynparza</i> MONO-OLA1	PARP inhibitor	1st-line BRCAwt ovarian cancer	PP	>2024
<i>Lynparza</i> OlympiA	PARP inhibitor	gBRCA adjuvant breast cancer	PP	Launched
<i>Orpathys</i> + <i>Imfinzi</i> SAMETA	MET inhibitor + PD-L1 mAb	1st-line papillary renal cell carcinoma	PP	>2024
<i>Tagrisso</i> + (Koselugo or <i>Orpathys</i>) TATTON	EGFR inhibitor + (MEK inhibitor or MET inhibitor)	advanced EGFRm NSCLC	PP Phase I	
<i>Tagrisso</i> + CTx FLAURA2	EGFR inhibitor + CTx	1st-line advanced EGFRm NSCLC		H2 2023
<i>Tagrisso</i> + <i>Orpathys</i> SAFFRON	EGFR inhibitor + MET inhibitor	advanced EGFRm NSCLC	PP	>2024
<i>Tagrisso</i> + <i>Orpathys</i> SAVANNAH	EGFR inhibitor + MET inhibitor	advanced EGFRm NSCLC	PP Phase II	
<i>Tagrisso</i> +/- CTx neoadjuvant NeoADAURA	EGFR inhibitor +/- CTx	stage II/III resectable EGFRm NSCLC		2024
<i>Tagrisso</i> ADAURA2	EGFR inhibitor	adjuvant EGFRm NSCLC stage Ia2-Ia3 following complete tumour resection		>2024
<i>Tagrisso</i> LAURA	EGFR inhibitor	stage III EGFRm NSCLC		H2 2023
<i>Tagrisso</i> (platform) ORCHARD	EGFR inhibitor + multiple novel oncology therapies	2nd-line EGFRm osimertinib-resistant NSCLC	PP Phase II	
CVRM				
<i>Andexxa</i>	anti-factor Xa reversal	urgent surgery		Phase II
<i>Farxiga/Forxiga</i> DAPA-MI	SGLT-2 inhibitor	prevention of heart failure and CV death following a myocardial infarction		n/a
<i>Farxiga/Forxiga</i> DELIVER	SGLT-2 inhibitor	worsening HF or CV death in patients with chronic heart failure (HFpEF)		Approved
<i>Lokelma</i> DIALIZE-Outcomes	potassium binder	CV outcomes in patients on chronic haemodialysis with hyperkalaemia		>2024
<i>Lokelma</i> STABILIZE-CKD	potassium binder	hyperkalaemia in CKD		>2024
roxadustat	hypoxia-inducible factor prolyl hydroxylase inhibitor	chemotherapy induced anaemia	PP Phase II	
roxadustat	hypoxia-inducible factor prolyl hydroxylase inhibitor	anaemia in myelodysplastic syndrome	PP	2024
<i>Xigduo XR/Xigduo</i>	SGLT-2 inhibitor/metformin FDC	type-2 diabetes		Launched

Development Pipeline

continued

Significant Life-cycle Management *continued*

Compound	Mechanism	Area Under Investigation	Additional Information	Estimated submission/ submission status
Respiratory & Immunology				
<i>Breztri/Trixeo</i> (PT010) KALOS LOGOS	LABA/LAMA/ICS	asthma		2024
<i>Fasenra</i> FJORD	IL-5R mAb	bullous pemphigoid		2024
<i>Fasenra</i> MANDARA	IL-5R mAb	eosinophilic granulomatosis with polyangiitis		2024
<i>Fasenra</i> NATRON	IL-5R mAb	hypereosinophilic syndrome		2024
<i>Fasenra</i> ORCHID	IL-5R mAb	nasal polyps	PP	>2024
<i>Fasenra</i> RESOLUTE	IL-5R mAb	COPD	PP	>2024
<i>Saphnelo</i> IRIS	Type I IFN receptor mAb	lupus nephritis	PP	>2024
<i>Saphnelo</i> TULIP-SC	Type I IFN receptor mAb	systemic lupus erythematosus (subcutaneous)	PP	>2024
<i>Tezspire</i> COURSE	TSLP mAb	COPD	PP Phase II	
<i>Tezspire</i> WAYPOINT	TSLP mAb	nasal polyps	PP	>2024
Rare Disease				
<i>Ultomiris</i>	anti-complement C5 mAb	dermatomyositis	Phase II/III	>2024
<i>Ultomiris</i>	anti-complement C5 mAb	haematopoietic stem cell transplant-associated thrombotic microangiopathy		>2024
<i>Ultomiris</i>	anti-complement C5 mAb	generalised myasthenia gravis		Launched
<i>Ultomiris</i>	anti-complement C5 mAb	subcutaneous, paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome		Approved
<i>Ultomiris</i> CHAMPION- NMOSD	anti-complement C5 mAb	neuromyelitis optica spectrum disorder		Under review